QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Cyclophosphamide
Related studies linked through entity extraction aliases.
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
- Status
- UNKNOWN
- Phase
- PHASE4
Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
- Status
- COMPLETED
- Phase
- PHASE1
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE3
The p53 Colorectal Cancer Trial
- Status
- TERMINATED
- Phase
- PHASE2
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2